United States Positron Emission Tomography Market Report by Product Type, Detector Type, Application, End-User, States and Companies Analysis 2026-2034

United States Positron Emission Tomography Market Size and Forecast 2026-2034

The United States Positron Emission Tomography (PET) market will be driven from US$ 330.83 million in 2025 to US$ 467.22 million in 2034. The market will expand at a CAGR of 3.91% from 2026-2034. This will be due to an increase in the prevalence rate of chronic diseases, advancements in technologies related to PET scanners, and an increase in demands for early and accurate detection methods within the healthcare facilities.

United States Positron Emission Tomography Market Outlook

Positron Emitting Tomography, abbreviated as PET, is an highly advanced medical imaging technique. It records various biochemical processes within the body. It requires a tiny injection of a radioactive compound, which releases positrons. As these interact with electrons, gamma rays are emitted, which are then detected by a PET scan and form three-dimensional images. It is widely utilized for diagnosing and staging various diseases, specifically cancers, neurological disorders, and cardiovascular disorders. Its utilization becomes highly successful because it detects dysfunction before structural changes occur, as compared to various imaging modalities.

In the United States, PET imaging has received widespread adoption because of its paramount importance in cancer treatment, wherein it assists in tumor detection and response measurement. Moreover, due to the prime prevalence of cancer and chronic illnesses within the United States, there continues to be widespread use of PET imaging. Advancements in technologies associated with PET/CT and PET/MR imaging have also ensured added accuracy and importance. Within the United States' healthcare infrastructure, there is rapid adoption due to developments within diagnostic facilities and a focus on early disease diagnosis.

Growth Drivers of United States Positron Emission Tomography Market

Increasing Incidence of Cancer and Chronic Diseases

The growing number of incidences of cancer, cardiovascular disease, and neurological disorders in the USA constitutes one of the most prominent driving forces for the regional PET market. Cancer diagnosis and its various stages, including treatment and subsequent recurrence, are some of the factors on which PET imaging significantly impacts. As cancer continues to increase, it becomes indispensable for cancer specialists wanting personalized treatment. The fact that PET imaging identifies and analyzes functional as well as metabolic functionalities and not anatomical functionalities makes it more superior compared to most prevailing imaging technologies. Also, programs for people with chronic illnesses emphasize early and precise diagnosis, making it an imperative imaging technique within hospitals and diagnostic centers. It is estimated that 129 million people with USA national status have at least 1 serious chronic illness based on various USA sources, such as heart disease, cancer, diabetes, and obesity. Also, 5 out of 10 leading sources causing deaths within USA today are either directly associated with or explain preventable and treatable sources. Within 2 decades, there has been a stable increase and will continue rising. A rising number of people within America continue facing multiple sources, with 42% presenting 2+ and 12+ at least 5 sources.

Technological Advancements and Hybrid Imaging Evolution

Rapid technological advancements have greatly boosted the adoption rate of PET within the United States. The anatomical details offered by hybrid imaging techniques like PET/CT and PET/MRI capabilities are superior compared with traditional stand-alone imaging systems. Moreover, advancements in detector materials and time-of-flight capabilities have enabled better resolution and lower dose imaging. Simultaneously, neurological, cardiac, and metabolic imaging is increasingly becoming feasible with advances in radiopharmaceuticals. Emerging theranostics practice, with targeted radiopharmaceuticals based on previous PET imaging, will also drive innovations and adoption within PET imaging. The NIH Awards R01 Grant to Develop Groundbreaking Medical Imaging Method - Published on 2023-02-20 00:00 - By University of California - Davis Health. Members with $\boxed{17}$ Lawrence Berkeley National Laboratory. The University of California, Davis, Department of Radiology received an R01 Grant research project award worth $2.5 million from the National Institute of Biomedical Imaging and Bioengineering at the NIH. The project aims at an unprecedented medical imaging method with immense benefits for cancer and heart and bone disease diagnosis.

Adding Diagnostic Centers and Reimbursement Assistance

The widespread growth in freestanding imaging centers and dedicated PET centers within the United States is yet another big factor contributing significantly to market growth. Access, wait times, and imaging volumes have greatly been improved with these centers. Also, because of generous remuneration polices surrounding PET imaging, particularly within oncology and cardiology, it makes business sense for imaging facilities. As more and more insurance structures validate and substantiate the benefits of PET on enhancing accuracy and lowering costs within healthcare on a long-term scale, more and more reimbursements are seen. Brightonix Imaging’s press release that its flagship product, PHAROS PET Scanner, achieved FDA clearance for commerical distribution within the United States. A new beginning in accuracy and efficiency within nuclear imaging technology makes Brightonix imaging leaders within medical and healthcare advancements.

Challenges Facing the United States PET Industry

Equipment Cost and Operating Cost

A disadvantage with PET scanners, especially with more advanced models like PET/CT and PET/MRI, relates to capital expenses. The set-up costs and subsequent expenditure for shielding make it expensive. Smaller centers and rural health facilities cannot readily invest in these technologies. Running PET facilities also incurs additional expenses in relation to acquisition and preparation costs of radiologs, personnel training or expertise, and compliance with standards. As a consequence, financial constraints hinder market growth and result in market domination by large centers. Upgrading or adopting new advancements in the market may be postponed owing to financial constraints.

Limitations with Supplying Radiotracers and Government Regulations

PET scanning procedures rely on short-half-life radiotracers that have to be manufactured and transported on a timely and reliable basis. The limited presence of cyclotron facilities in some regions, logistical problems, and strict handling procedures could affect radiotracer downstream supply chains. Delays will directly affect scanning schedules and times. A large number of regulations follow and control handling procedures for radioactive materials. Moreover, there are prolonged verification and approval procedures to develop new types of PET radiotracers. A high dependence on specific radiopharmaceuticals due to advances in neurological, cardiologic, and theranostic procedures could pose an issue for the United States market structure due to better and timely access.

United States Full-Ring PET Scanners Market

Full-ring PET scanners have dominated the U.S. market because of their superior sensitivity, higher image resolution, and much shorter acquisition times. These are systems with a continuous ring of detectors which capture more photons and realize more correct metabolic imaging. They are widely installed in hospitals, cancer centers, and major diagnostic facilities supporting high patient throughput. Full-ring PET scanners excel in oncology, given their precision and reproducibility are pivotal in decision-making on treatments. More advanced capabilities allow full-ring systems to be integrated with time-of-flight technology, AI-driven reconstructions, and hybrid imaging modules. Although these scanners involve heavy investments in capital, their diagnostic accuracy and operational efficiency justify their adoption in high-volume centers. With ongoing improvements in detector materials and digital PET technologies, full-ring systems remain the gold standard in U.S. PET imaging infrastructure.

United States Bismuth Germanium Oxide (BGO) PET Market

BGO-based scanners have had a long-standing presence in the U.S. market due to their cost-effectiveness and strong stopping power for high-energy photons. Those crystals provide reliable performance in conventional PET imaging, particularly in an environment where ultra-high resolution is not the primary requirement. BGO detectors are suited for oncology-focused PET centers looking for value and durability. While newer materials like LYSO and LFS have entered the market with faster response times, BGO remains relevant in budget-sensitive installations. Its resilience, longer decay time tolerance, and proven track record make it a dependable choice for many diagnostic providers. As demand grows in smaller community hospitals and mid-sized centers, BGO PET scanners hold a steady market presence due to their price-performance balance.

United States Lutetium Fine Silicate (LFS) PET Market

LFS-based PET detectors are a next-generation advance that offers faster response times and a very high light output. This is enhancing timing resolution, thereby reducing time-of-flight imaging noise and yielding clearer images. Within the U.S., LFS-based PET scanners are increasingly adopted by high-performance diagnostic centers and research institutions oriented toward precision imaging. The higher efficiency supports lower-dose protocols and shorter scan times. This improves patient comfort while improving operational throughput. Besides, LFS technology is very valuable for detecting small lesions and supporting sophisticated neurological or cardiac imaging studies. Although more costly versus older crystal technologies, such LFS scanners are in tune with the general trend in the industry towards improved clinical accuracy. Strong growth is foreseen for the segment as health providers modernize their infrastructure for imaging.

United States Cardiology PET Market

PET is playing an ever-growing role in U.S. cardiology, thanks to the precision of the modality in the assessment of myocardial perfusion, blood flow, and metabolic activity. Compared to traditional SPECT, PET offers superior diagnostic accuracy in the detection of coronary artery disease, the evaluation of ischemia, and interventional strategy. Since cardiovascular diseases remain at the forefront of health burdens, there is an increased dependency by cardiologists on PET to enhance diagnosis and patient stratification. This ability to quantify myocardial blood flow offers active insights for personalized treatment planning. New radiotracers in cardiology PET improve diagnostic specificity and allow early detection of the disease. With cardiac-specific PET programs being widely adopted by hospitals and diagnostic centers, especially in countries facing aging populations and high cardiovascular risk factors, cardiology is among the fastest-growing application segments in PET imaging.

United States Neurology PET Market

The neurology segment of the U.S. PET market has rapid growth due to the increasing cases of neurodegenerative disorders like Alzheimer's disease, Parkinson's disease, epilepsy, and several other neurodegenerative diseases. PET allows for the early detection of metabolic changes in brain tissue, often well before structural imaging will determine abnormalities. New tracers targeting amyloid, tau, and dopamine transporters definitely make PET one of the powerful diagnostic tools for neurological conditions. PET aids precision medicine approaches by elucidating neurologist thinking about disease progression and assessment of therapeutic responses. Greater awareness among the public and a developing clinical demand for early dementia diagnosis have been leading to dedicated neuroimaging programs at more hospitals. Obviously, growth in the neurology segment of PET in the United States would have sustainment in these factors: growing emphasis on brain health, aging population, and research into neurotherapeutics.

United States PET Diagnostic Centers Market

Diagnostic centers function as the hub of PET market growth, making accessible and specialized imaging available outside of hospital networks. Such facilities enable high patient throughput, competitive pricing, and operational specialization. Early adopters of advanced hybrid systems, PET diagnostic centers focus on imaging service quality and physician referrals. By being geographically distributed, the access by patients is improved in suburban and rural settings where hospital PET departments are limited. Many centers would go into agreements with radiopharmaceutical suppliers to have tracers in consistent supply. With value-based care focused on efficient diagnostics, outpatient PET centers will be increasingly strong positions for payers and providers. Fully supportive of cost savings, speedy scheduling, and patient convenience, their business model helps them account for a significant share of the growth in the U.S. PET market.

California Positron Emission Tomography Market

California is amongst one of the most advanced PET imaging markets of the U.S., mainly due to its presence of world-class healthcare systems, large research institutions, and a high concentration of cancer centers within the state. The state’s diverse population and robust clinical research ecosystem drive strong demand for advanced diagnostic technologies. PET utilization is especially strong in oncology and neurology; a strong referral network exists among hospitals and outpatient diagnostic centers in the state. California also fronts in the adoption of hybrid PET/MRI and digital PET systems. Its biomedical innovation environment encourages clinical trials of new tracers and new imaging workflows. Despite the high operational cost, reimbursement structures and strong patient volumes sustain the expansion. The state leads in advanced healthcare, hence positioning the state as a key driver of national technology adoption.

New York Positron Emission Tomography Market

New York's PET market is anchored by major academic medical centers, cancer treatment facilities, and densely populated urban regions. High rates of cancer screening, strong physician networks, and extensive healthcare infrastructure support heavy PET utilization. New York hospitals are one of the early adopters in the country when a new PET technology is introduced to the market, largely to support oncology, neurology, and cardiology programs. New tracer and advanced imaging technique development is supported by the state's research ecosystem. While regulatory and reimbursement environments are complex, they are highly supportive of evidence-based imaging. Patient demand is driven both from a preventive healthcare culture and specialist referrals. New York remains one of the highest-demand PET markets in the United States, underpinned by strong diagnostic center presence and continuous investment in the infrastructural foundation.

Texas Positron Emission Tomography Market

Texas offers healthy growth in the PET market, driven by its large population, expansion of healthcare networks, and an ever-growing prevalence of chronic diseases. Major cities like Houston, Dallas, and San Antonio are hubs for world-renowned cancer centers and cardiology programs involving heavy utilization of PET imaging. Moreover, diagnostic centers have been expanding into suburban and semi-urban areas, aimed at augmenting patient accessibility. The diversified demographic profile of the state contributes to high demand for imaging procedures within oncology, cardiac care, and neurological diagnostics. Texas also offers relatively lower operational costs than coastal states, thereby encouraging facility expansion and equipment upgrades. This contributes to strong hospital investments and increased supply infrastructure of tracers in Texas, ranking it as one of the fastest-growing PET markets in the United States.

Arizona Positron Emission Tomography Market

Arizona's PET market is steadily growing, due to population growth, aging, and the higher prevalence of chronic diseases. Cities like Phoenix and Tucson have modern diagnostic centers and hospital PET departments and are seeing growing adoptions of hybrid PET/CT systems. Oncology remains the main application, driven by high cancer screening and treatment demand. The state's warm climate attracts retirees, boosting demand for neurology and cardiology PET imaging. While logistics around radiotracers can be challenging in rural areas of the state, the ever-expanding network of cyclotrons is making supplies more reliable. Arizona has strong potential for growth of PET, with modernization of healthcare infrastructure, a rise in insurance cover, and increasing awareness of the benefits of advanced imaging.

Market Segmentations

Product Type

• Full-Ring PET Scanners
• Partial-Ring PET Scanners

Detector Type

• Bismuth Germanium Oxide (BGO)
• Lutetium Oxyorthosilicate (LSO)
• Lutetium Fine Silicate (LFS)
• Lutetium Yttrium Orthosilicate (LYO)
• Gadolinium Oxyorthosilicate (GSO)

Application

• Cardiology
• Neurology
• Oncology
• Others

End-User

• Hospitals and Clinics
• Diagnostic Centers
• Others

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• Agfa Healthcare (Dedalus Group)
• GE Healthcare
• Koninklijke Philips NV
• Neusoft Medical Systems
• Positron Corporation
• Oncovision (Bruker)
• Mediso Medical Imaging Systems Ltd.
• Siemens Healthineers AG
• Segami Corporation
• Hitachi Ltd.

Report Details: